Paratus Sciences

Executive Summary

Paratus Sciences is a private biotechnology company founded in 2021 that leverages the unique evolutionary adaptations of bats to discover and develop novel therapeutics for human diseases. By integrating genomics and informatics, the company's proprietary platform analyzes bat biology to identify promising therapeutic targets, initially focusing on immunological, inflammatory, and cardiometabolic conditions with high unmet need. Based in New York, Paratus Sciences operates at the intersection of comparative biology and drug discovery, aiming to translate insights from nature into novel treatment approaches. Although the company is still in early stages without disclosed pipeline or funding details, its differentiated strategy and focus on bat-derived targets could offer advantages in addressing complex diseases. With a novel discovery engine and a niche approach, Paratus Sciences represents an early-stage opportunity in the biotechnology space, though visibility into specific programs and milestones remains limited.

Upcoming Catalysts (preview)

• 2026Series A Funding Announcement70% success
• 2026Lead Therapeutic Program Nomination55% success
• 2026Publication of Bat Biology Discovery Platform Results60% success